No significant differences were detected in the number of tumor‐infiltrating CD68+ macrophages, CD8+, and CD138+ lymphocytes among patients naïve to SRL at surgery and responsive to post‐surgery SRL treatment and patients naïve to SRL at surgery and not responsive to post‐surgery SRLs, as reported in Table 3. The gene discussed is CD68; the disease is neoplasm.